Natasja J H Raijmakers1, M Zijlstra2,3, J van Roij2, O Husson4,5, S Oerlemans2, L V van de Poll-Franse2,6,7. 1. The Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, The Netherlands. n.raijmakers@iknl.nl. 2. The Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, The Netherlands. 3. Department of Medical Oncology, Radboud MC, Nijmegen, The Netherlands. 4. Department of Medical Psychology, Radboud University MC, Nijmegen, The Netherlands. 5. Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK. 6. CoRPS-Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands. 7. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS: Between 2008 and 2015, cancer patients were invited to participate in PROFILES (Patient Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship) registry studies. Patients were eligible for inclusion in this secondary analysis if they had been invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in their last year of life (N = 892). Four hundred fifty-eight patients (51%) responded. Descriptive statistics were used to describe the HRQoL of cancer patients in the last 3 months of life (N = 61), the last 3-6 months (N = 110), the last 6-9 months (N = 138), or the last 9-12 months of their life (N = 129). RESULTS: Patients in the last 3 months report a significant lower HRQoL, lower functioning, and higher symptom burden of fatigue and appetite loss compared to patients in different time periods before death (p < 0.008). Clinical relevance of the differences for global QoL, cognitive, and social functioning was large. Patients' HRQoL in the last year of life was significantly lower than that of the normative population (p < 0.001). CONCLUSIONS: All aspects of HRQoL are considerably impaired in patients with advanced cancer, with a marked lower HRQoL in the final months of life. This marked decline of HRQoL in the final months of life may be an indicator of approaching death and serve as an important trigger for end-of-life communication and decision-making about subsequent treatment and supportive care.
PURPOSE: The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancerpatients stratified by four periods of time before death. PATIENTS AND METHODS: Between 2008 and 2015, cancerpatients were invited to participate in PROFILES (Patient Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship) registry studies. Patients were eligible for inclusion in this secondary analysis if they had been invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in their last year of life (N = 892). Four hundred fifty-eight patients (51%) responded. Descriptive statistics were used to describe the HRQoL of cancerpatients in the last 3 months of life (N = 61), the last 3-6 months (N = 110), the last 6-9 months (N = 138), or the last 9-12 months of their life (N = 129). RESULTS:Patients in the last 3 months report a significant lower HRQoL, lower functioning, and higher symptom burden of fatigue and appetite loss compared to patients in different time periods before death (p < 0.008). Clinical relevance of the differences for global QoL, cognitive, and social functioning was large. Patients' HRQoL in the last year of life was significantly lower than that of the normative population (p < 0.001). CONCLUSIONS: All aspects of HRQoL are considerably impaired in patients with advanced cancer, with a marked lower HRQoL in the final months of life. This marked decline of HRQoL in the final months of life may be an indicator of approaching death and serve as an important trigger for end-of-life communication and decision-making about subsequent treatment and supportive care.
Entities:
Keywords:
Advanced cancer; Palliative care; Population-based cohort; Quality of life
Authors: Johannes M Giesinger; Lisa M Wintner; Anne S Oberguggenberger; Eva M Gamper; Michael Fiegl; Hubert Denz; Georg Kemmler; August Zabernigg; Bernhard Holzner Journal: J Palliat Med Date: 2011-06-28 Impact factor: 2.947
Authors: Marianne Ahlner Elmqvist; Marit S Jordhøy; Kristin Bjordal; Stein Kaasa; Magnus Jannert Journal: Support Care Cancer Date: 2008-06-26 Impact factor: 3.603
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Simon Noah Etkind; Barbara A Daveson; Wingfai Kwok; Jana Witt; Claudia Bausewein; Irene J Higginson; Fliss E M Murtagh Journal: J Pain Symptom Manage Date: 2014-08-15 Impact factor: 3.612
Authors: Nicole Je Horevoorts; Pauline Aj Vissers; Floortje Mols; Melissa Sy Thong; Lonneke V van de Poll-Franse Journal: J Med Internet Res Date: 2015-05-07 Impact factor: 5.428
Authors: Kim Ah Nicolaije; Nicole Pm Ezendam; Johanna Ma Pijnenborg; Dorry Boll; Maria Caroline Vos; Roy Fpm Kruitwagen; Lonneke V van de Poll-Franse Journal: J Med Internet Res Date: 2016-07-08 Impact factor: 5.428
Authors: Sophie C Regueme; Iñaki Echeverria; Nicolas Monéger; Jessica Durrieu; Maïté Becerro-Hallard; Sophie Duc; Aurelie Lafargue; Cécile Mertens; Hamid Laksir; Joël Ceccaldi; Sandrine Lavau-Denes; Thierry Dantoine; Jon Irazusta; Isabelle Bourdel-Marchasson Journal: Support Care Cancer Date: 2020-05-20 Impact factor: 3.603